Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01592097 · ClinicalTrials.gov registry record
Exploratory Study to Assess Clinical Response to Gilenya® (Fingolimod) in Hispanics With RRMS
A clinical trial, sponsored by University of Southern California.
- Completed
- Registry status
- 51
- Enrollment target
NCT01592097 is a clinical trial that has completed, run by University of Southern California. The registered enrollment target is 51 participants.
The verdict
NCT01592097 has completed, sponsored by University of Southern California.
- COMPLETED
- Registry status
- 51 participants
- Enrollment target
Study Summary
Gilenya (fingolimod) is approved for multiple sclerosis. However, it is unclear of its clinical effect in the Hispanics with MS given that clinical studies had limited representation of this population. It is also unclear if Gilenya would be as effective in individuals with disease predominantly affecting the optic nerve and spinal cord (OSMS) commonly seen in Asian populations. Objectives: To compare the clinical response of Gilenya® (fingolimod) in relapsing remitting OSMS and MS of Hispanic descent using ancestral markers as a biomarker of treatment response and clinical disease state.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 51 participants |
| Start Date | 2012-06 |
| Est. Completion | 2018-04 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01592097
The ClinicalTrials.gov registry entry for NCT01592097 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 51 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Southern California, which has 617 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 0 interventions.
NCT01592097 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01592097 about?
NCT01592097 is a clinical study titled "Exploratory Study to Assess Clinical Response to Gilenya® (Fingolimod) in Hispanics With RRMS". Gilenya (fingolimod) is approved for multiple sclerosis. However, it is unclear of its clinical effect in the Hispanics with MS given that clinical studies had limited representation of this population. It is also unclear if Gilenya would be as effective in individuals with disease predominantly aff...
What is the current status of trial NCT01592097?
This trial is currently completed. The enrollment target is 51 participants. The study started on 2012-06. Estimated completion is 2018-04.
Who is sponsoring clinical trial NCT01592097?
This trial is sponsored by University of Southern California, which has 617 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.